< Back to companies
Oxford Cancer Analytics

Oxford Cancer Analytics

Oxford, United Kingdom

Oxford Cancer Analytics is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Share
Shareable draft
Get Involved in Oxford Cancer Analytics

Company Info

Founded
2020
Website
www.oxcan.org/

Categories

CancerScreening & Early DetectionDiagnosticsAI / ML

Disease Areas

Technologies

Machine LearningLiquid BiopsyAI in DiagnosticsDiagnostic Platforms
Only accessible to MedStartr community members. Join now

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Sign in to join the conversation.

Sign in to comment
Be the first to comment.

What do you think of Oxford Cancer Analytics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Your scores and comments are shown with your review on this company's profile.

Get Involved in Oxford Cancer Analytics
💬

Hi, I'm Syggy!

MedStartr's AI healthcare innovation superhero. Just click me for whatever you need! 🥰

💬
Hi, I'm Syggy
your healthcare innovation buddy
💬

Ask Syggy anything

What MedStartr is, how it can help you, events, joining...

You're chatting as a visitor: this conversation stays in this browser, isn't linked to any account, and doesn't move over if you join. Join free